NCI Glioblastoma Therapeutics Network U19 Grant 2026

NCI Glioblastoma Therapeutics Network U19 Grant 2026

Due Date: 10/01/2026

The National Cancer Institute (NCI) Glioblastoma Therapeutics Network (GTN) U19 Grant supports multi-institutional teams developing novel therapeutic agents for adult glioblastoma (GBM), with particular emphasis on therapies capable of crossing the blood-brain barrier and advancing rapidly into early clinical testing.

Each GTN team is expected to move promising agents from late preclinical development through IND-enabling studies and into pilot or Phase 0/1 clinical studies. NCI plans to commit approximately $4.4 million in FY 2027 to support 3–4 awards, with individual applications allowed to request up to $700,000 in direct costs per year for up to five years.

Eligibility Criteria

  • Eligible applicants include U.S. public and private institutions of higher education.
  • Eligible nonprofit and for-profit organizations, including small businesses, may apply.
  • Foreign organizations are not eligible to apply.
  • Non-U.S. components of U.S. organizations are not eligible, and foreign components are not allowed.
  • Each application must propose a multi-institutional team involving at least two institutions.
  • Each lead institution may submit only one GTN U19 application.
  • Applications may be either New or Renewal.

Funding Details

  • Funding mechanism: U19 Research Program Cooperative Agreement.
  • Maximum budget: $700,000 in direct costs per year.
  • Maximum project duration: 5 years.
  • Total planned FY 2027 funding: Approximately $4.4 million in total costs.
  • Expected number of awards: 3–4.

Deadline

  • Posted: August 31, 2026.
  • Open date: September 1, 2026.
  • Application deadline: October 1, 2026.
  • Applications are due by 5:00 PM local time of the applicant organization.
  • Earliest project start: July 2027.
  • NOFO expiration: October 2, 2026.

Further Information

  • Clinical activities should be integrated into the U19 with the goal of advancing candidate agents from preclinical development into pilot or Phase 0/1 clinical trials during the award period.
  • Official program announcement: View RFA-CA-27-005
  • Simpler.Grants.gov: View the funding opportunity
  • Grants.gov: View on Grants.gov